Steven P. Coen - Apr 17, 2025 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role
Chief Accounting Officer
Signature
/s/ Karen Tepichin, Attorney-in-Fact
Stock symbol
DNA
Transactions as of
Apr 17, 2025
Transactions value $
-$7,261
Form type
4
Date filed
4/23/2025, 05:03 PM
Previous filing
Mar 10, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNA Class A Common Stock Options Exercise +587 +7.33% 8.6K Apr 17, 2025 Direct F1
transaction DNA Class A Common Stock Options Exercise +156 +1.81% 8.76K Apr 17, 2025 Direct F1
transaction DNA Class A Common Stock Options Exercise +1.06K +12.12% 9.82K Apr 17, 2025 Direct F1
transaction DNA Class A Common Stock Sale -$7.26K -997 -10.16% $7.28 8.82K Apr 21, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNA Restricted Stock Units Options Exercise -587 -3.84% 14.7K Apr 17, 2025 Class A Common Stock 587 Direct F1, F3
transaction DNA Restricted Stock Units Options Exercise -156 -2.77% 5.47K Apr 17, 2025 Class A Common Stock 156 Direct F1, F4
transaction DNA Restricted Stock Units Options Exercise -1.06K -24.99% 3.18K Apr 17, 2025 Class A Common Stock 1.06K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2 Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
F3 The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.
F4 The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.
F5 The RSUs vest as follows: 25% vested on April 16, 2025; 25% will vest on July 16, 2025; 25% will vest on October 16, 2025; and 25% will vest on January 16, 2026.

Remarks:

Chief Accounting Officer